down arrow

Telomir Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87975F1049
USD
1.37
0.02 (1.48%)

Dec 18

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.351.42

52 Week

1.125.40
Valuation
Technical
Day's Volume

CASH

240.69 k

Shareholding (Mar 2025)

FII

0.14%

Held by 6 FIIs

DII

91.46%

Held by 9 DIIs

Promoter

0.00%

How big is Telomir Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Telomir Pharmaceuticals, Inc. has a market capitalization of 55.36 million, with net sales of 0.00 million and a net profit of -12.52 million over the last four quarters. The company's shareholder's funds are 0.64 million, and total assets are 1.32 million.

Market Cap: As of Jun 18, Telomir Pharmaceuticals, Inc. has a market capitalization of 55.36 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Telomir Pharmaceuticals, Inc. reported net sales of 0.00 million and a net profit of -12.52 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 0.64 million, while total assets were reported at 1.32 million.

Read More

What does Telomir Pharmaceuticals, Inc. do?

22-Jun-2025

Telomir Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $55.36 million. Key metrics include a debt equity ratio of 0.40 and a return on equity of 1,653.27%.

Overview: <BR>Telomir Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 55.36 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.40 <BR>Return on Equity: 1,653.27% <BR>Price to Book: -55.36<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Telomir Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of July 18, 2025, Telomir Pharmaceuticals, Inc. shows a mildly bearish trend with mixed technical indicators, including a mildly bullish weekly MACD, bearish daily moving averages, and significant underperformance against the S&P 500, with year-to-date and one-year returns of -66.02% and -76.67%, respectively.

As of 18 July 2025, the technical trend for Telomir Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the moving averages indicate a bearish stance on the daily timeframe. The Bollinger Bands show a mildly bearish trend on the weekly chart. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -66.02% compared to the S&P's 12.22%, and a one-year return of -76.67% versus the S&P's 17.14%. Overall, the current technical stance is mildly bearish, with key indicators reflecting mixed signals across different timeframes.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 40 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.75

stock-summary
Return on Equity

-1,653.27%

stock-summary
Price to Book

39.71

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.14%
0%
-2.14%
6 Months
-22.16%
0%
-22.16%
1 Year
-70.66%
0%
-70.66%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Telomir Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
-2.82
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.40
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.78%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-63.99
EV to EBIT
-5.19
EV to EBITDA
-5.19
EV to Capital Employed
-63.59
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 8 Schemes (8.4%)

Foreign Institutions

Held by 6 Foreign Institutions (0.14%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -264.29% vs 12.50% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.10",
          "val2": "-1.50",
          "chgp": "-240.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.10",
          "val2": "-1.40",
          "chgp": "-264.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -25.95% vs -1,355.56% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.20",
          "val2": "-3.90",
          "chgp": "-212.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.30",
          "val2": "1.60",
          "chgp": "168.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-7.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.50",
          "val2": "-13.10",
          "chgp": "-25.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.10
-1.50
-240.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.10
-1.40
-264.29%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -264.29% vs 12.50% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.20
-3.90
-212.82%
Interest
4.30
1.60
168.75%
Exceptional Items
0.00
-7.50
100.00%
Consolidate Net Profit
-16.50
-13.10
-25.95%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -25.95% vs -1,355.56% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Telomir Pharmaceuticals, Inc. stock-summary
stock-summary
Telomir Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."